Pressroom & News

Mikael Dolsten has spent decades pushing the boundaries of science, medicine, and technology—overseeing the development of 35+ approved medicines and vaccines and helping lead Pfizer’s historic COVID-19 response. Now, he brings that expertise to Formation Bio.

The new round was led by a16z, with significant participation from Sanofi. Formation Bio will use the funds to grow its drug pipeline and continue to expand its tech and AI platform.

The three companies are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle.

Formation Bio (formerly known as TrialSpark) licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio.

Formation Bio (formerly known as TrialSpark) announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio.